Benefits of Sotagliflozin in Diabetes Management
Recent clinical trials have shown encouraging results for sotagliflozin, a new treatment option for managing type 2 diabetes. These findings not only confirm its effectiveness but also emphasize its role in improving time-in-range (TIR) for patients on basal insulin therapy. This innovative treatment employs a dual-action mechanism, targeting both SGLT1 and SGLT2 proteins, which provides a thorough approach to glucose regulation.
Understanding Time-In-Range and Its Importance
Time-in-range is a vital concept in diabetes management, as it measures how long a person's blood glucose levels stay within a target range. The American Diabetes Association recommends aiming for a TIR of at least 70%. In this context, a recent analysis from the SOTA-INS CGM Phase 3 trial demonstrated that sotagliflozin helps patients meet this target more efficiently, achieving 15.3 hours with the 200 mg dose and 15.9 hours with the 400 mg dose.
The Study Details
This Phase 3 trial featured a randomized control group specifically designed to evaluate the effects of sotagliflozin on TIR using continuous glucose monitoring (CGM). The initial results indicate a significant reduction in time-above-range (TAR), which is crucial for lowering the risks linked to high blood glucose levels. Meanwhile, only slight increases were noted in time-below-range (TBR).
Findings from EASD Conference
These findings were presented at a major diabetes conference, where researchers discussed how once-daily dosing of sotagliflozin could improve patient outcomes. Dr. Julio Rosenstock, a respected figure in clinical research, highlighted the dual mechanism of sotagliflozin, suggesting it could broaden therapeutic options for those with type 2 diabetes.
The Role of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has been at the forefront of developing sotagliflozin, utilizing their unique gene science approach. This innovative drug acts as an oral inhibitor of both SGLT1 and SGLT2, which are crucial for managing glucose levels through different mechanisms in the body. Lexicon's dedication to addressing the complex nature of diabetes positions them as leaders in biopharmaceutical innovation.
Exploring Future Potential
Although Lexicon is not currently seeking direct indications for treating type 2 diabetes, the research surrounding sotagliflozin shows great promise. The positive results from the SOTA-INS study further suggest that ongoing clinical exploration could improve therapeutic options for effectively managing diabetes.
Innovation and Commitment to Patient Care
Lexicon Pharmaceuticals is committed to leveraging advanced genomic insights to develop effective treatments for various health conditions. Through innovative initiatives like the Genome5000™ program, they have made significant strides in identifying new protein targets for potential medications. Sotagliflozin exemplifies Lexicon's dedication to finding solutions for a wide array of health challenges, including neuropathic pain and chronic kidney disease.
Contact Information for Inquiries
If you have questions about the recent findings or other company-related information, investors and media representatives can contact Lisa DeFrancesco at Lexicon Pharmaceuticals. For prompt assistance, inquiries can be sent via email to lexinvest@lexpharma.com.
Frequently Asked Questions
What is sotagliflozin and how does it help diabetes patients?
Sotagliflozin is an oral medication that inhibits both SGLT1 and SGLT2, which are essential for glucose regulation. This helps lower blood sugar levels for diabetes patients.
How does the SOTA-INS CGM Phase 3 trial measure effectiveness?
The trial assesses the average change in the percentage of time spent within the target glucose range (70-180 mg/dL) for patients taking sotagliflozin compared to those on a placebo.
What are the targets set by the American Diabetes Association for TIR?
The ADA recommends achieving a TIR of at least 70%, which translates to approximately 17 hours a day out of a 24-hour period.
How can patients access sotagliflozin?
Sotagliflozin is available via prescription, and patients should discuss its suitability with their healthcare providers as part of their treatment plans.
Where can I find more information about Lexicon Pharmaceuticals?
For additional information on Lexicon’s products and developments, including sotagliflozin, visit their official website at www.lexpharma.com.
